$EMMA
Emmaus Life Sciences, Inc. Stock $emma

$emma Overview Financials Valuation SEC Filings Company Website

2014 Q3 Form 10-Q Financial Statement

#000114420414050194 Filed on August 14, 2014

Income Statement

Concept	2014 Q3	2014 Q2	2013 Q2
Revenue	$20.00K	$30.00K	$30.00K
YoY Change	-60.0%	0.0%	0.0%
Cost Of Revenue	$0.00	$10.00K	$40.00K
YoY Change	-100.0%	-75.0%	0.0%
Gross Profit	$20.00K	$20.00K	-$10.00K
YoY Change	100.0%	-300.0%
Gross Profit Margin	100.0%	66.67%	-33.33%
Selling, General & Admin	$610.0K	$638.7K	$736.6K
YoY Change	-21.79%	-13.29%	-16.63%
% of Gross Profit	3050.0%	3193.5%
Research & Development	$310.0K	$400.0K	$430.0K
YoY Change	-27.91%	-6.98%	59.26%
% of Gross Profit	1550.0%	2000.0%
Depreciation & Amortization	$0.00	$0.00	$0.00
YoY Change
% of Gross Profit	0.0%	0.0%
Operating Expenses	$920.0K	$1.041M	$1.205M
YoY Change	-23.97%	-13.66%	1.61%
Operating Profit	-$900.0K	-$1.015M	-$1.179M
YoY Change	-25.0%	-13.97%	2.25%
Interest Expense	$20.00K	-$1.300K	-$183.3K
YoY Change	-128.57%	-99.29%	-76.11%
% of Operating Profit
Other Income/Expense, Net	$40.00K	-$1.300K	-$152.8K
YoY Change	-100.69%	-99.15%	-103.14%
Pretax Income	-$840.0K	-$1.016M	-$1.332M
YoY Change	-88.1%	-23.74%	-135.84%
Income Tax	$0.00	$1.800K	$0.00
% Of Pretax Income
Net Earnings	-$840.0K	-$1.019M	-$1.334M
YoY Change	-88.12%	-23.63%	-136.9%
Net Earnings / Revenue	-4200.0%	-3396.0%	-4446.67%
Basic Earnings Per Share			-$0.03
Diluted Earnings Per Share	-$10.50M	-$12.75M	-$0.03
COMMON SHARES
Basic Shares Outstanding	101.7M shares	100.5M shares	42.69M shares
Diluted Shares Outstanding			42.69M shares

Balance Sheet

Concept	2014 Q3	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.240M	$60.00K	$670.0K
YoY Change	-2.36%	-91.04%	3250.0%
Cash & Equivalents	$1.241M	$63.90K	$671.6K
Short-Term Investments
Other Short-Term Assets	$60.00K	$100.0K	$100.0K
YoY Change	0.0%	0.0%	25.0%
Inventory
Prepaid Expenses
Receivables	$9.300K	$5.800K	$12.10K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.308M	$166.8K	$790.2K
YoY Change	-4.09%	-78.89%	507.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.700K	$10.60K	$19.10K
YoY Change	-48.21%	-44.5%	-4.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$19.30K	$19.90K	$22.00K
YoY Change	-10.23%	-9.55%	-26.67%
Total Long-Term Assets	$28.00K	$30.50K	$41.10K
YoY Change	-26.89%	-25.79%	-31.5%
TOTAL ASSETS
Total Short-Term Assets	$1.308M	$166.8K	$790.2K
Total Long-Term Assets	$28.00K	$30.50K	$41.10K
Total Assets	$1.336M	$197.3K	$831.3K
YoY Change	-4.71%	-76.27%	337.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$868.9K	$890.9K	$3.000M
YoY Change	-65.15%	-70.3%	0.33%
Accrued Expenses	$370.0K	$400.0K	$2.130M
YoY Change	-53.16%	-81.22%	95.41%
Deferred Revenue
YoY Change
Short-Term Debt	$1.480M	$0.00	$6.520M
YoY Change		-100.0%	-4.68%
Long-Term Debt Due	$3.500K	$4.600K	$7.000K
YoY Change	-51.39%	-34.29%	-30.0%
Total Short-Term Liabilities	$1.617M	$1.548M	$11.94M
YoY Change	-54.54%	-87.04%	-34.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$10.00K
YoY Change	-100.0%	-100.0%	0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$1.481M	$3.300K	$7.900K
YoY Change	24581.67%	-58.23%	-21.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.617M	$1.548M	$11.94M
Total Long-Term Liabilities	$1.481M	$3.300K	$7.900K
Total Liabilities	$3.098M	$1.551M	$11.94M
YoY Change	-13.04%	-87.02%	-34.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$59.21M	-$58.38M	-$49.48M
YoY Change	4.71%	17.98%
Common Stock	$101.7K	$100.6K	$49.80K
YoY Change	9.71%	102.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.762M	-$1.354M	-$11.11M
YoY Change
Total Liabilities & Shareholders Equity	$1.336M	$197.3K	$831.3K
YoY Change	-4.71%	-76.27%	337.53%

Cashflow Statement

Concept	2014 Q3	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$840.0K	-$1.019M	-$1.334M
YoY Change	-88.12%	-23.63%	-136.9%
Depreciation, Depletion And Amortization	$0.00	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$730.0K	-$720.0K	-$740.0K
YoY Change	-27.0%	-2.7%	105.56%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.900M	0.000	700.0K
YoY Change	19.5%	-100.0%	250.0%
NET CHANGE
Cash From Operating Activities	-730.0K	-720.0K	-740.0K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	1.900M	0.000	700.0K
Net Change In Cash	1.170M	-720.0K	-40.00K
YoY Change	98.31%	1700.0%	-75.0%
FREE CASH FLOW
Cash From Operating Activities	-$730.0K	-$720.0K	-$740.0K
Capital Expenditures			$0.00
Free Cash Flow			-$740.0K
YoY Change			124.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	25900	USD
CY2014Q2	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	26100	USD
	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	83300	USD
	cnso	Neurometric Information Services Revenue NeurometricInformationServicesRevenue	110400	USD
CY2013Q2	us-gaap	Direct Operating Costs DirectOperatingCosts	38800	USD
CY2014Q2	us-gaap	Direct Operating Costs DirectOperatingCosts	5200	USD
	us-gaap	Direct Operating Costs DirectOperatingCosts	105800	USD
	us-gaap	Direct Operating Costs DirectOperatingCosts	72100	USD
CY2013Q2	cnso	Research Research	53100	USD
CY2014Q2	cnso	Research Research	20700	USD
	cnso	Research Research	156400	USD
	cnso	Research Research	92900	USD
CY2013Q2	cnso	Product Development ProductDevelopment	376800	USD
CY2014Q2	cnso	Product Development ProductDevelopment	376100	USD
	cnso	Product Development ProductDevelopment	705400	USD
	cnso	Product Development ProductDevelopment	1050500	USD
CY2013Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	83400	USD
CY2014Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	105600	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	254900	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	290500	USD
CY2013Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	653200	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	533100	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1863700	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1523700	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	1205300	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	1040700	USD
	us-gaap	Operating Expenses OperatingExpenses	3086200	USD
	us-gaap	Operating Expenses OperatingExpenses	3029700	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1179400	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1014600	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3002900	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2919300	USD
CY2013Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-183300	USD
CY2014Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1300	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1213600	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2900	USD
CY2013Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	556300	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1105200	USD
CY2013Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	-30500	USD
CY2014Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	62200	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
CY2013Q2	cnso	Offering Costs OfferingCosts	0	USD
CY2014Q2	cnso	Offering Costs OfferingCosts	0	USD
	cnso	Offering Costs OfferingCosts	2500	USD
	cnso	Offering Costs OfferingCosts	0	USD
CY2013Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2014Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-97600	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-152800	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1300	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-819600	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1102300	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1332200	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1015900	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3822500	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1817000	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1800	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	800	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4300	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1332200	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1017700	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-3823300	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1821300	USD
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1800	USD
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-1100	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-15200	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-4400	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-1334000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1018800	USD
	us-gaap	Net Income Loss NetIncomeLoss	-3838500	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1825700	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.03
CY2014Q2	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.01
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.17
	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-0.02
CY2013Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.00
CY2014Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.00
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.00
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42691256	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	100573956	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22336772	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	98546223	shares
	dei	Entity Incorporation State Country Name EntityIncorporationStateCountryName	Delaware
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1987-03-20
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	180000000	shares
	us-gaap	Debt Instrument Interest Rate Effective Percentage Rate Range Maximum DebtInstrumentInterestRateEffectivePercentageRateRangeMaximum	0.09	pure
CY2014Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	USD
	us-gaap	Property Plant And Equipment Depreciation Methods PropertyPlantAndEquipmentDepreciationMethods	straight-line basis
	us-gaap	Depreciation Depreciation	10100	USD
	us-gaap	Depreciation Depreciation	7800	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58500	USD
CY2014Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	67100	USD
CY2014Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.00
CY2014Q2	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	451400	USD
	us-gaap	Advertising Expense AdvertisingExpense	6000	USD
	us-gaap	Advertising Expense AdvertisingExpense	0	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	76448279	shares
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	637200	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2012Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	824400	USD
CY2014Q2	cnso	Debt Instrument Conversion Vote Percentage DebtInstrumentConversionVotePercentage	1	pure
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	5792500	USD
CY2012Q3	us-gaap	Convertible Debt ConvertibleDebt	8012000	USD
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	76488279	shares
	cnso	Debt Conversion Original Debt Principal Amount DebtConversionOriginalDebtPrincipalAmount	9613900	USD
CY2013	cnso	Debt Conversion Original Debt Principal Amount DebtConversionOriginalDebtPrincipalAmount	9612100	USD
	cnso	Debt Conversion Original Debt Interest Amount DebtConversionOriginalDebtInterestAmount	1661100	USD
CY2013	cnso	Debt Conversion Original Debt Interest Amount DebtConversionOriginalDebtInterestAmount	1661000	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	11275000	USD
CY2013	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	11273100	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63900	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1273600	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5800	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26600	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	97100	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	63700	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	166800	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	1363900	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10600	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16800	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19900	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21500	USD
CY2014Q2	us-gaap	Assets Assets	197300	USD
CY2013Q3	us-gaap	Assets Assets	1402200	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	890900	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2493200	USD
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	58300	USD
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	24200	USD
CY2014Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	342000	USD
CY2013Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	763100	USD
CY2014Q2	us-gaap	Deferred Revenue DeferredRevenue	45900	USD
CY2013Q3	us-gaap	Deferred Revenue DeferredRevenue	0	USD
CY2014Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	4600	USD
CY2013Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	7200	USD
CY2014Q2	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	205800	USD
CY2013Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	268500	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1547500	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	3556200	USD
CY2014Q2	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	3300	USD
CY2013Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	6000	USD
CY2014Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3300	USD
CY2013Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	1550800	USD
CY2013Q3	us-gaap	Liabilities Liabilities	3562200	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	100600	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	92700	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	56922300	USD
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	11490575	shares
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	439400	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3509425	shares
CY2013Q1	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	283400	USD
CY2012Q4	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	15000	USD
CY2013Q4	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	180000	USD
CY2013Q1	cnso	Volume Of Shares Traded On Open Market VolumeOfSharesTradedOnOpenMarket	36700	USD
CY2014Q2	cnso	Total Stock Shares Authorized TotalStockSharesAuthorized	195000000	shares
CY2013Q4	cnso	Options To Purchase Shares Of Common Stock OptionsToPurchaseSharesOfCommonStock	700000	shares
CY2013Q4	cnso	Common Stock Exercise Price Per Share CommonStockExercisePricePerShare	0.25
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1334000	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1018800	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3838500	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1825700	USD
CY2014Q2	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	5400	USD
CY2014Q2	us-gaap	Capital Leases Future Minimum Payments Due In Two And Three Years CapitalLeasesFutureMinimumPaymentsDueInTwoAndThreeYears	2500	USD
CY2014Q2	us-gaap	Capital Leases Future Minimum Payments Due In Four And Five Years CapitalLeasesFutureMinimumPaymentsDueInFourAndFiveYears	0	USD
CY2014Q2	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2014Q2	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	7900	USD
CY2013Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	5900	USD
CY2014Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	44400	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-1142600	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54298000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58376400	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-56550700	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	-1353500	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-2160000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	197300	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1402200	USD
CY2013Q2	us-gaap	Share Based Compensation ShareBasedCompensation	293500	USD
CY2014Q2	us-gaap	Share Based Compensation ShareBasedCompensation	172600	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	987000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	839700	USD
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9749594	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2300000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2014Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	57095	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11992499	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12049594	shares
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.00
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2014Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2013Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.25
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2014Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.13
CY2014Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2013Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.86
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.86
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.86
CY2013	cnso	Warrants Forfeited WarrantsForfeited	1617345	shares
CY2013Q3	cnso	Warrants Outstanding WarrantsOutstanding	1497556	shares
CY2014Q2	cnso	Warrants Outstanding WarrantsOutstanding	1041447	shares
CY2013	cnso	Warrants Issued Exercise Price WarrantsIssuedExercisePrice	3.03
	cnso	Warrants Issued Exercise Price WarrantsIssuedExercisePrice	4.37
CY2013	cnso	Warrants Forfeited Exercise Price WarrantsForfeitedExercisePrice	3.00
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q1	cnso	Common Stock Shares Authorized Increased Number CommonStockSharesAuthorizedIncreasedNumber	180000000	shares
CY2013Q1	cnso	Common Stock Shares Authorized Increased Number CommonStockSharesAuthorizedIncreasedNumber	150000000	shares
CY2014Q2	cnso	Common Stock Shares Authorized Increased Number CommonStockSharesAuthorizedIncreasedNumber	15000000	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100627409	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100627409	shares
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	66700	USD
CY2014Q2	us-gaap	Long Term Debt Maturing In Years Two And Three LongTermDebtMaturingInYearsTwoAndThree	0	USD
CY2014Q2	us-gaap	Long Term Debt LongTermDebt	16900	USD
CY2014Q2	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	35300	USD
CY2014Q2	cnso	Deferred Compensation Liability Related Party Current DeferredCompensationLiabilityRelatedPartyCurrent	73500	USD
CY2013Q3	cnso	Deferred Compensation Liability Related Party Current DeferredCompensationLiabilityRelatedPartyCurrent	294500	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	13000	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two And Three Years OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears	67400	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four And Five Years OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears	0	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	80400	USD
CY2014Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	16900	USD
CY2014Q2	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	69900	USD
CY2014Q2	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	0	USD
CY2014Q2	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	0	USD
CY2014Q2	us-gaap	Contractual Obligation ContractualObligation	105200	USD
CY2013Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	12400	USD
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	12200	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	35300	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	32800	USD
CY2014Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1200	USD
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	us-gaap	Interest Paid Net InterestPaidNet	2557	USD
	us-gaap	Interest Paid Net InterestPaidNet	3300	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4300	USD
	cnso	Placement Agent Warrants Issued PlacementAgentWarrantsIssued	66200	USD
	cnso	Placement Agent Warrants Issued PlacementAgentWarrantsIssued	44100	USD
	cnso	Offering Costs Cash Flow Non Cash Investing And Financing Activities OfferingCostsCashFlowNonCashInvestingAndFinancingActivities	2500	USD
	cnso	Offering Costs Cash Flow Non Cash Investing And Financing Activities OfferingCostsCashFlowNonCashInvestingAndFinancingActivities	0	USD
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	92716562	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	92716562	shares
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	10100	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	7800	USD
	cnso	Amortization Of Debt Discount On Bridge Notes AmortizationOfDebtDiscountOnBridgeNotes	661000	USD
	cnso	Amortization Of Debt Discount On Bridge Notes AmortizationOfDebtDiscountOnBridgeNotes	0	USD
	cnso	Issuance Of Warrants For Financing Services IssuanceOfWarrantsForFinancingServices	66200	USD
	cnso	Issuance Of Warrants For Financing Services IssuanceOfWarrantsForFinancingServices	0	USD
	cnso	Noncash Interest Expense NoncashInterestExpense	550200	USD
	cnso	Noncash Interest Expense NoncashInterestExpense	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-300	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-20800	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	59700	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	33400	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-8800	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-101500	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	201700	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	-421100	USD
	cnso	Increase Decrease In Deferred Compensation Exchange For Common Stock IncreaseDecreaseInDeferredCompensationExchangeForCommonStock	-178300	USD
	cnso	Increase Decrease In Deferred Compensation Exchange For Common Stock IncreaseDecreaseInDeferredCompensationExchangeForCommonStock	0	USD
	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	0	USD
	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	45900	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2052300	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2568300	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1400	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1400	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	4200	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5300	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1368300	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1362700	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1431000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2726800	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1425700	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	675900	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-12000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-67100	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	663900	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1209700	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7700	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	671600	USD
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	-13074700	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	987000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	839700	USD
	cnso	Stock Issued For Private Placement Shares Purchases StockIssuedForPrivatePlacementSharesPurchases	1431000	USD
	cnso	Stock Issued During Period Value Issued In Lieu Of Cash To Creditors StockIssuedDuringPeriodValueIssuedInLieuOfCashToCreditors	361500	USD
	cnso	Stock Issued During Period Value Warrant Exercise StockIssuedDuringPeriodValueWarrantExercise	0	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	7900	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3375900	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1362700	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-11113500	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> <strong>1. NATURE OF OPERATIONS</strong></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Organization and Nature of Operations</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">CNS Response, Inc. (“CNS,” “we,” “us,” “our,” or the “Company”) was incorporated in <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> Delaware</font> on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">March 20, 1987</font>, under the name Age Research, Inc.  Prior to January 16, 2007, the Company (then called Strativation, Inc.) was a “shell company” with nominal assets and our sole business was to identify, evaluate and investigate various companies to acquire or with which to merge.  On January 16, 2007, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with CNS Response, Inc., a California corporation formed on January 11, 2000 (“CNS California”), and CNS Merger Corporation, a California corporation and the Company’s wholly-owned subsidiary (“MergerCo”) pursuant to which the Company agreed to acquire CNS California in a merger transaction wherein MergerCo would merge with and into CNS California, with CNS California being the surviving corporation (the “Merger”). On March 7, 2007, the Merger closed, CNS California became a wholly-owned subsidiary of the Company, and on the same date the corporate name was changed from Strativation, Inc. to CNS Response, Inc.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company is a clinical decision support company with a patented commercial neurometric platform to predict drug response for the treatment of brain disorders, including depression, anxiety, bipolar disorder and post-traumatic stress disorder (“PTSD”).  The Company has commenced a reimbursed 2,000 patient trial at Walter Reed National Military Medical Center (“Walter Reed”) and Fort Belvoir Community Hospital (“Fort Belvoir”) focused on patients with depression, PTSD and mild traumatic brain injury in order to support clinical decisions in the treatment of depression and related disorders.  We are being reimbursed by Walter Reed at a study-specific rate which includes a prorated element for study expenses for each Psychiatric Electroencephalographic Evaluation Registry (“PEER”) Outcome report rendered in the study. Enrollment of study subjects commenced in May 2013, and has continued through May 15, 2014. On May 15, 2014, the study’s principal investigator was directed to suspend enrollment of new subjects into the study pending further investigation of findings stemming from a routine audit. Treatment and tracking of individuals already enrolled in the clinical trial were allowed to continue. The Company has been supporting Investigating Officer’s requests for information via the study leader, Dr. Brett Schneider. We have been advised by WRNMMC leadership that the investigation should complete during August 2014 and study enrollment should resume shortly thereafter.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company acquired the Neuro-Therapy Clinic, Inc. (“NTC”) on January 15, 2008, to provide behavioral health care services.  NTC’s operations were discontinued effective September 30, 2012, so that the Company could focus its limited resources on the clinical trial at Walter Reed. NTC is accounted for as a discontinued operation <i>(Refer to Note 3. Discontinued Operations).</i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: #548dd4" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the Company’s 2014 annual meeting of stockholders, held on May 13, 2014 (the “2014 Annual Meeting”), the Company’s common stockholders voted to reappoint the Company’s existing board of directors (the “Board”) to serve until the next annual meeting and until any successor is elected and qualified.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> At the 2014 Annual Meeting, the Company’s stockholders also voted in favor of the following proposals:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <table style="MARGIN-TOP: 0pt; WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">to amend the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Charter”) in order to increase the number of shares of Common Stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> per share (“Common Stock”), authorized for issuance under the Charter from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 180,000,000</font>; and</font></div> </td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.75in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">·</font></div> </td> <td> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Times New Roman, Times, Serif">to ratify the selection by the Audit Committee of the Company’s Board of Anton & Chia, LLP as the Company’s independent registered accounting firm for the fiscal year ending September 30, 2014</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><i> </i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Going Concern Uncertainty</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which contemplate continuation of the Company as a going concern. The Company has a limited operating history and its operations are subject to certain problems, expenses, difficulties, delays, complications, risks and uncertainties frequently encountered in the operation of a new business. These risks include the ability to obtain adequate financing on a timely basis, the failure to develop or supply technology or services to meet the demands of the marketplace, the failure to attract and retain qualified personnel, competition within the industry, government regulation and the general strength of regional and national economies.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s continued operating losses and limited capital raise substantial doubt about its ability to continue as a going concern. The Company has limited cash resources for its operations and will need to raise additional funds to meet its obligations as they become due.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">To date, the Company has financed its cash requirements primarily from debt and equity financings.  The Company will need to raise additional funds immediately to continue its operations and to raise substantial additional funds before the Company can increase demand for its PEER Online services (formerly known as rEEG services). Until it can generate a sufficient amount of revenues to finance its cash requirements, which it may never do, the Company has to finance future cash needs primarily through public or private equity offerings, debt financings, borrowings or strategic collaborations. The Company’s liquidity and capital requirements depend on several factors, including the rate of market acceptance of its services, the future profitability of the Company, the rate of growth of the Company’s business and other factors described elsewhere in this Current Report on Form 10-Q.  The Company continues to explore additional sources of capital but there is substantial doubt as to whether any financing arrangement will be available in amounts and on terms acceptable to the Company to permit it to continue operations. The accompanying audited and unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Between October 4, 2013 and February 14, 2014, the Company issued an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,900,000</font> shares of its Common Stock, at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.25</font> per share, in private placements to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">29</font> accredited investors. The gross proceeds to the Company were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,475,000</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; COLOR: #548dd4" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The private placements were made pursuant to an exemption from registration afforded by Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D thereunder, as the shares of Common Stock were issued to accredited investors, without a view to distribution, and not through any general solicitation or advertisement. The shares of Common Stock have not been, and will not be, registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	361500	USD
	cnso	Shares Issued For Officer Salaries SharesIssuedForOfficerSalaries	7900	USD
	cnso	Shares Issued For Officer Salaries SharesIssuedForOfficerSalaries	0	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	CNS RESPONSE, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0000822370
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	CNSO
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	101667409	shares
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	3375900	USD
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	66200	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-12000	USD
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-67100	USD

Files In Submission

Name	View Source	Status
0001144204-14-050194-index-headers.html	Edgar Link	pending
0001144204-14-050194-index.html	Edgar Link	pending
0001144204-14-050194.txt	Edgar Link	pending
0001144204-14-050194-xbrl.zip	Edgar Link	pending
cnso-20140630.xml	Edgar Link	completed
cnso-20140630.xsd	Edgar Link	pending
cnso-20140630_cal.xml	Edgar Link	unprocessable
cnso-20140630_def.xml	Edgar Link	unprocessable
cnso-20140630_lab.xml	Edgar Link	unprocessable
cnso-20140630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v385747_10q.htm	Edgar Link	pending
v385747_ex10-88.htm	Edgar Link	pending
v385747_ex31-1.htm	Edgar Link	pending
v385747_ex31-2.htm	Edgar Link	pending
v385747_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMMA
Emmaus Life Sciences, Inc. Stock $emma

2014 Q3 Form 10-Q Financial Statement

#000114420414050194 Filed on August 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMMA Emmaus Life Sciences, Inc. Stock $emma

2014 Q3 Form 10-Q Financial Statement

#000114420414050194 Filed on August 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMMA
Emmaus Life Sciences, Inc. Stock $emma